Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Emerging Pipeline of Neuromodulators and Injectable Fillers
Description
The talk reviewed the near-term pipeline for cosmetic neuromodulators and injectable fillers, focusing on products and indications that may arrive in the U.S. over the next one to five years. For neuromodulators, it highlighted investigational masseter treatment for aesthetic lower-face slimming, ready-to-use liquid botulinum toxin formulations that could reduce reconstitution errors and improve convenience, and Relabotulinum toxin A, which is already approved in some regions and showed strong efficacy with a relatively long duration in large trials. It also discussed trenibotulinum toxin E, a rapid-onset, short-duration toxin that may be useful for same-day events or as a teaching tool, with reassuring safety and immunogenicity data. The presentation then covered recombinant botulinum toxins such as IPN10200 and YY003, which are designed for more tailored performance. On the filler side, it covered new temple injection guidance, emerging HA uses for tech neck, and the growing popularity of biostimulators like calcium hydroxylapatite, PLLA, PCL, and HA-CaHA combinations. These agents aim to stimulate collagen and elastin while providing structural support, with new indications being explored for cellulite, thighs, buttocks, décolletage, and facial rejuvenation. The speaker emphasized that the future may include more durable, engineered, and ultimately regenerative filler technologies, including biomaterial scaffolds that encourage the body to rebuild tissue rather than simply replace volume.
View moreConclusions
- The next 1 to 5 years in aesthetic medicine will likely bring more convenient, safer, and more customizable botulinum toxin products, including ready-to-use, rapid-onset, and recombinant formulations.
- RelabotulinumtoxinA appears to provide strong efficacy for glabellar lines with a favorable safety profile and a potentially longer-lasting clinical effect than standard expectations.
- TrenibotulinumtoxinE offers very rapid onset but a short duration, making it useful for time-sensitive cosmetic treatment needs while maintaining an apparently acceptable safety and immunogenicity profile.
- Future botulinum toxins may be engineered to better match specific clinical goals, potentially reducing toxicity and improving performance for particular facial regions or indications.
- New filler development is moving toward next-generation hyaluronic acid and hybrid HA/CaHA products that aim to combine structural support with biostimulatory longevity.
- Biostimulators such as PCL and novel PLLA formulations seem to produce persistent collagen-driven improvement and may last longer than conventional hyaluronic acid fillers in selected indications.
- Current and emerging filler indications are expanding beyond classic facial volume restoration to areas such as temples, neck lines, cellulite, decolletage, thighs, and buttocks.
- The field is moving toward truly regenerative aesthetic treatments in which injectable scaffolds or matrices stimulate the body to rebuild tissue rather than simply replace volume.
- Overall, the research presented suggests that aesthetic injectables will become more product-specific, more durable, and more regenerative over the coming years.
- Shridharani et al. Aesthetic Surgery Journal. 2024. READY-1 phase 3 trial in glabellar lines.
- Barr JR, Moura H, Boyer AE, Woolfitt AR, Kalb SR, Pavlopoulos A, McWilliams LG, Schmidt JG, Martinez RA, Ashley DL. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis. 2005 Oct;11(10):1578-83.#10.3201/eid1110.041279
- Aguilera, McCarthy, Khalifian, Lorenc, Goldie, and Chernoff. Aesthetic Surgery Journal, 2023.
- Cavallini M, Braz A, Greiner-Krüger D, Lipko-Godlewska S, Patel T, Safa M, Shotter S, Gálvez FU, Kerson G. Global Recommendations for Facial Rejuvenation Using a Hyaluronic Acid and Calcium Hydroxyapatite Hybrid Injectable. J Cosmet Dermatol. 2026 Jan;25(1):e70608.#10.1111/jocd.70608
- Zhao H, Ren R, Bao S, Qian W, Ma X, Wang R, Li X, Fang R, Sun Q, Tian Y, Zhu C, Shi J. Efficacy and Safety of Polycaprolactone in Treating Nasolabial Folds: A Prospective, Multicenter, and Randomized Controlled Trial. Facial Plast Surg. 2023 Jun;39(3):300-306.#10.1055/a-1954-3986
- Uridales-Gálvez, Benítez, and Díaz. Journal of Cosmetic Dermatology. PLLA-LASYNPRO.
- Bertossi et al. Facial Plastic Surgery. PLLA-LASYNPRO.
- Int. J. Mol. Sci. 2024, 25(16), 8955.